scholarly journals FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic

Life ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 143
Author(s):  
Yoshio Sumida ◽  
Masashi Yoneda ◽  
Katsutoshi Tokushige ◽  
Miwa Kawanaka ◽  
Hideki Fujii ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Fatty Liver Disease ◽  
Transient Elastography ◽  
Diagnostic Algorithm ◽  
Metabolic Dysfunction ◽  
Nonalcoholic Fatty Liver ◽  
Invasive Test ◽  
Related Mortality

The prevalence of obesity or metabolic syndrome is increasing worldwide (globally metabodemic). Approximately 25% of the adult general population is suffering from nonalcoholic fatty liver disease (NAFLD), which has become a serious health problem. In 2020, global experts suggested that the nomenclature of NAFLD should be updated to metabolic-dysfunction-associated fatty liver disease (MAFLD). Hepatic fibrosis is the most significant determinant of all cause- and liver -related mortality in MAFLD. The non-invasive test (NIT) is urgently required to evaluate hepatic fibrosis in MAFLD. The fibrosis-4 (FIB-4) index is the first triaging tool for excluding advanced fibrosis because of its accuracy, simplicity, and cheapness, especially for general physicians or endocrinologists, although the FIB-4 index has several drawbacks. Accumulating evidence has suggested that vibration-controlled transient elastography (VCTE) and the enhanced liver fibrosis (ELF) test may become useful as the second step after triaging by the FIB-4 index. The leading cause of mortality in MAFLD is cardiovascular disease (CVD), extrahepatic malignancy, and liver-related diseases. MAFLD often complicates chronic kidney disease (CKD), resulting in increased simultaneous liver kidney transplantation. The FIB-4 index could be a predictor of not only liver-related mortality and incident hepatocellular carcinoma, but also prevalent and incident CKD, CVD, and extrahepatic malignancy. Although NITs as milestones for evaluating treatment efficacy have never been established, the FIB-4 index is expected to reflect histological hepatic fibrosis after treatment in several longitudinal studies. We here review the role of the FIB-4 index in the management of MAFLD.

New therapy for fatty liver

2018 ◽  
Vol 1 (2) ◽  
pp. 24-28
Author(s):  
Tanita Suttichaimongkol
Keyword(s):  
Oxidative Stress ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Liver Insulin Resistance ◽  
Alcoholic Fatty Liver Disease ◽  
Related Mortality

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of death from liver cirrhosis, endstage liver disease, and hepatocellular carcinoma. It is also associated with increased cardiovasculardisease and cancer related mortality. While lifestyle modifications are the mainstay of treatment,only a proportion of patients are able to make due to difficult to achieve and maintain, and so moretreatment options are required such as pharmacotherapy. This review presents the drugs used inmanaging NAFLD and their pharmacologic targets. Therapies are currently directed towards improvingthe metabolic status of the liver, insulin resistance, cell oxidative stress, apoptosis, inflammation orfibrosis. Several agents are now in large clinical trials and within the next few years, the availability oftherapeutic options for NAFLD will be approved.     Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, fibrosis, cirrhosis  

scholarly journals Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview

Biomolecules ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 473
Author(s):  
Helena Castañé ◽  
Gerard Baiges-Gaya ◽  
Anna Hernández-Aguilera ◽  
Elisabet Rodríguez-Tomàs ◽  
Salvador Fernández-Arroyo ◽  
...  
Keyword(s):  
Machine Learning ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Predictive Biomarkers ◽  
Metabolic Dysfunction ◽  
Complex Situation ◽  
Nonalcoholic Fatty Liver ◽  
General Overview ◽  
Diagnosis Accuracy

Hepatic biopsy is the gold standard for staging nonalcoholic fatty liver disease (NAFLD). Unfortunately, accessing the liver is invasive, requires a multidisciplinary team and is too expensive to be conducted on large segments of the population. NAFLD starts quietly and can progress until liver damage is irreversible. Given this complex situation, the search for noninvasive alternatives is clinically important. A hallmark of NAFLD progression is the dysregulation in lipid metabolism. In this context, recent advances in the area of machine learning have increased the interest in evaluating whether multi-omics data analysis performed on peripheral blood can enhance human interpretation. In the present review, we show how the use of machine learning can identify sets of lipids as predictive biomarkers of NAFLD progression. This approach could potentially help clinicians to improve the diagnosis accuracy and predict the future risk of the disease. While NAFLD has no effective treatment yet, the key to slowing the progression of the disease may lie in predictive robust biomarkers. Hence, to detect this disease as soon as possible, the use of computational science can help us to make a more accurate and reliable diagnosis. We aimed to provide a general overview for all readers interested in implementing these methods.

Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Kaveh Hajifathalian ◽  
Zaid Tafesh ◽  
Russell Rosenblatt ◽  
Sonal Kumar ◽  
Edwin A. Homan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Related Mortality ◽  
Statin Use

SYSTEMATIC REVIEW WITH COMPARATIVE ANALYSIS OF RECOMMENDATIONS FOR THE DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE

2021 ◽  
pp. 107-112
Author(s):  
N.A. TOKTOGULOVA ◽  
Keyword(s):  
Liver Disease ◽  
Comparative Analysis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Asia Pacific ◽  
Nonalcoholic Fatty Liver ◽  
Invasive Test ◽  
Risk Patients ◽  
Definition Of

A review of the available literature has shown that the current epidemic of nonalcoholic fatty liver disease (NAFLD) is closely related with the widespread prevalence of metabolic risk factors worldwide, such as obesity, type 2 diabetes, and dyslipidemia. In parallel with the increasing availability of effective antiviral drugs, NAFLD is rapidly becoming the most common cause of chronic liver disease in Western countries, and a similar trend is expected in Eastern countries in the coming years. This epidemic and its aftermath have prompted experts from around the world to identify effective strategies for the diagnosis, management and treatment of NAFLD. Various scientific associations from America, Europe and the Asia-Pacific region have offered recommendations based on the most recent data on NAFLD. These recommendations are consistent with the key elements of NAFLD management, but at the same time, there are significant differences in some critical points. We have identified clinical guidelines from 8 different scientific societies with a worldwide reputation, and tried to conduct a systematic and comparative analysis of the presented protocols. Differences were noted in: definition of NAFLD, screening for NAFLD in high-risk patients, a non-invasive test proposed to diagnose NAFLD and identify NAFLD patients with severe fibrosis, follow-up protocols, and finally, treatment strategy

Sign in / Sign up

Export Citation Format

Share Document